(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
I thought I knew the night sky, but what I saw from the Canary Islands left me speechless - 2Step by step instructions to Safeguard Your Teeth During Sports Exercises
- 3A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- 4Vote In favor of Your Number one Sort Of Blossoms
- 5Kansas school officials report high student illness, dismiss early
- Guinea-Bissau's coup called a 'sham' by West African political figures
- 5 Home Improvement Styles: Decision in favor of Your #1
- Knesset sets special panel to fast-track Karhi’s communications reform
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- Gunmen open fire near Israeli consulate in Istanbul in possible ISIS-linked attack
- 10 High priority Contraptions for Tech Aficionados
- Iran war triggering Easter staycation boom
- Experience Sports in Dubai: A Daredevil's Aide
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
